term,TopCut_highestMinuslogP_up,maximum_MinuslogP_up,sum_MinuslogP_up,times_significant_up,FirstTopCut_significant_up,PEBBA_score_up
Fertilization,100,-0.0,0.0,0.0,0,0.5
Reproduction,100,-0.0,0.0,0.0,0,0.5
Miscellaneous transport and binding events,100,-0.0,0.0,0.0,0,0.5
Uptake and actions of bacterial toxins,1500,0.22989479564991924,0.547373001998805,0.0,0,0.8369341450940667
Dopamine Neurotransmitter Release Cycle,100,-0.0,0.0,0.0,0,0.5
Serotonin Neurotransmitter Release Cycle,100,-0.0,0.0,0.0,0,0.5
Norepinephrine Neurotransmitter Release Cycle,100,-0.0,0.0,0.0,0,0.5
Acetylcholine Neurotransmitter Release Cycle,100,-0.0,0.0,0.0,0,0.5
Glutamate Neurotransmitter Release Cycle,100,-0.0,0.0,0.0,0,0.5
Neurotransmitter Release Cycle,100,-0.0,0.0,0.0,0,0.5
GABA synthesis release reuptake and degradation,100,-0.0,0.0,0.0,0,0.5
Na+slashCl_ dependent neurotransmitter transporters,100,-0.0,0.0,0.0,0,0.5
Amine compound SLC transporters,100,-0.0,0.0,0.0,0,0.5
Transport of inorganic cationsslashanions and amino acidsslasholigopeptides,750,0.2602171608125759,0.836196229710712,0.0,0,0.7938047597851282
Amino acid transport across the plasma membrane,750,0.460298780269238,2.912748100915734,0.0,0,0.8311953940002875
Amino acid and oligopeptide SLC transporters,750,0.3279722151162562,1.821704725562346,0.0,0,0.8073127450936526
Zinc transporters,100,-0.0,0.0,0.0,0,0.5
Metal ion SLC transporters,100,-0.0,0.0,0.0,0,0.5
Amino acid synthesis and interconversion transamination,100,-0.0,0.0,0.0,0,0.5
Transport of vitamins nucleosides and related molecules,100,-0.0,0.0,0.0,0,0.5
Disorders of transmembrane transporters,100,-0.0,0.0,0.0,0,0.5
Surfactant metabolism,100,-0.0,0.0,0.0,0,0.5
ABC transporters in lipid homeostasis,100,-0.0,0.0,0.0,0,0.5
ABC_family proteins mediated transport,100,-0.0,0.0,0.0,0,0.5
Signaling by Retinoic Acid,100,-0.0,0.0,0.0,0,0.5
RA biosynthesis pathway,100,-0.0,0.0,0.0,0,0.5
The canonical retinoid cycle in rods twilight vision,100,-0.0,0.0,0.0,0,0.5
Visual phototransduction,100,-0.0,0.0,0.0,0,0.5
Retinoid metabolism and transport,1500,0.3334455210403917,0.5745427776521792,0.0,0,0.8529748865988599
Metabolism of fat_soluble vitamins,1500,0.3334455210403917,0.48718236127451037,0.0,0,0.8529748865988599
HS_GAG degradation,1300,0.05194072049486629,0.1994319210011962,0.0,0,0.7938606938730237
Diseases associated with glycosaminoglycan metabolism,100,-0.0,0.0,0.0,0,0.5
Defective B3GALT6 causes EDSP2 and SEMDJL1,100,-0.0,0.0,0.0,0,0.5
Defective B4GALT7 causes EDS progeroid type,100,-0.0,0.0,0.0,0,0.5
Defective B3GAT3 causes JDSSDHD,100,-0.0,0.0,0.0,0,0.5
A tetrasaccharide linker sequence is required for GAG synthesis,100,-0.0,0.0,0.0,0,0.5
Heparan sulfateslashheparin HS_GAG metabolism,1400,0.009826492517979402,0.009826492517979402,0.0,0,0.791165504182469
HS_GAG biosynthesis,100,-0.0,0.0,0.0,0,0.5
Chondroitin sulfateslashdermatan sulfate metabolism,100,-0.0,0.0,0.0,0,0.5
Chondroitin sulfate biosynthesis,100,-0.0,0.0,0.0,0,0.5
Keratan sulfate biosynthesis,1150,0.2727309519872042,1.8001498224312482,0.0,0,0.8266297014248367
Keratan sulfateslashkeratin metabolism,950,0.6375118398532623,5.925197602028563,0.0,0,0.8705097400943396
Diseases of glycosylation,100,-0.0,0.0,0.0,0,0.5
Diseases associated with O_glycosylation of proteins,100,-0.0,0.0,0.0,0,0.5
Defective B3GALTL causes Peters_plus syndrome PpS,850,0.25376729878252624,0.7881968105058401,0.0,0,0.8018446957930259
O_glycosylation of TSR domain_containing proteins,850,0.12847856119010595,0.33635892706959314,0.0,0,0.77539578125117
O_linked glycosylation of mucins,100,-0.0,0.0,0.0,0,0.5
Termination of O_glycan biosynthesis,650,0.40851982925323316,2.985375505880614,0.0,0,0.81275349591409
Defective GALNT12 causes colorectal cancer 1 CRCS1,100,-0.0,0.0,0.0,0,0.5
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis HFTC,100,-0.0,0.0,0.0,0,0.5
Defective C1GALT1C1 causes Tn polyagglutination syndrome TNPS,100,-0.0,0.0,0.0,0,0.5
Elastic fibre formation,100,-0.0,0.0,0.0,0,0.5
Molecules associated with elastic fibres,100,-0.0,0.0,0.0,0,0.5
ECM proteoglycans,100,-0.0,0.0,0.0,0,0.5
Integrin cell surface interactions,800,0.3771011554025471,2.958964395379753,0.0,0,0.8208541860819432
Syndecan interactions,350,0.6007717550664724,7.190592382769147,0.0,0,0.8089791102505554
Non_integrin membrane_ECM interactions,350,0.17352205694379447,1.209543272181517,0.0,0,0.707158211964368
Laminin interactions,100,-0.0,0.0,0.0,0,0.5
Assembly of collagen fibrils and other multimeric structures,100,-0.0,0.0,0.0,0,0.5
Collagen formation,100,-0.0,0.0,0.0,0,0.5
Collagen biosynthesis and modifying enzymes,100,-0.0,0.0,0.0,0,0.5
Collagen degradation,950,0.6375118398532623,6.635814735639429,0.0,0,0.8705097400943396
Activation of Matrix Metalloproteinases,100,-0.0,0.0,0.0,0,0.5
Hyaluronan metabolism,100,-0.0,0.0,0.0,0,0.5
Activation of SMO,100,-0.0,0.0,0.0,0,0.5
Synthesis of glycosylphosphatidylinositol GPI,100,-0.0,0.0,0.0,0,0.5
Post_translational modification: synthesis of GPI_anchored proteins,100,-0.0,0.0,0.0,0,0.5
Common Pathway of Fibrin Clot Formation,100,-0.0,0.0,0.0,0,0.5
Formation of Fibrin Clot Clotting Cascade,650,0.3814193796883901,2.26931268547212,0.0,0,0.807609645965359
Intrinsic Pathway of Fibrin Clot Formation,100,-0.0,0.0,0.0,0,0.5
Gamma carboxylation hypusine formation and arylsulfatase activation,100,-0.0,0.0,0.0,0,0.5
Glycosphingolipid metabolism,950,0.7067543167878418,6.088872247174139,0.034482758620689655,950,0.8791725870328108
Sphingolipid metabolism,950,0.7067543167878418,7.378879369380564,0.034482758620689655,950,0.8791725870328108
Sphingolipid de novo biosynthesis,100,-0.0,0.0,0.0,0,0.5
TNF receptor superfamily TNFSF members mediating non_canonical NF_kB pathway,100,-0.0,0.0,0.0,0,0.5
TNFs bind their physiological receptors,100,-0.0,0.0,0.0,0,0.5
Beta defensins,100,-0.0,0.0,0.0,0,0.5
Defensins,100,-0.0,0.0,0.0,0,0.5
Depolymerisation of the Nuclear Lamina,100,-0.0,0.0,0.0,0,0.5
Gap junction assembly,850,0.12847856119010595,0.33635892706959314,0.0,0,0.77539578125117
Gap junction trafficking,100,-0.0,0.0,0.0,0,0.5
Gap junction trafficking and regulation,100,-0.0,0.0,0.0,0,0.5
Golgi Associated Vesicle Biogenesis,100,-0.0,0.0,0.0,0,0.5
trans_Golgi Network Vesicle Budding,100,-0.0,0.0,0.0,0,0.5
Clathrin derived vesicle budding,100,-0.0,0.0,0.0,0,0.5
Lysosome Vesicle Biogenesis,100,-0.0,0.0,0.0,0,0.5
Nef_mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,100,-0.0,0.0,0.0,0,0.5
The role of Nef in HIV_1 replication and disease pathogenesis,100,-0.0,0.0,0.0,0,0.5
Trafficking of GluR2_containing AMPA receptors,100,-0.0,0.0,0.0,0,0.5
Trafficking of AMPA receptors,100,-0.0,0.0,0.0,0,0.5
Glutamate Binding Activation of AMPA Receptors and Synaptic Plasticity,100,-0.0,0.0,0.0,0,0.5
EGFR downregulation,100,-0.0,0.0,0.0,0,0.5
WNT5A_dependent internalization of FZD4,100,-0.0,0.0,0.0,0,0.5
Recycling pathway of L1,100,-0.0,0.0,0.0,0,0.5
L1CAM interactions,100,-0.0,0.0,0.0,0,0.5
Interaction between L1 and Ankyrins,100,-0.0,0.0,0.0,0,0.5
Biosynthesis of the N_glycan precursor dolichol lipid_linked oligosaccharide LLO and transfer to a nascent protein,100,-0.0,0.0,0.0,0,0.5
Synthesis of substrates in N_glycan biosythesis,100,-0.0,0.0,0.0,0,0.5
Sialic acid metabolism,900,0.3215618777670921,2.9739536109162694,0.0,0,0.8187460584293257
N_Glycan antennae elongation,1150,0.4974262681961858,4.643020923173293,0.0,0,0.8615188181922231
N_glycan antennae elongation in the medialslashtrans_Golgi,1150,0.4974262681961858,4.878768787991689,0.0,0,0.8615188181922231
Intra_Golgi traffic,100,-0.0,0.0,0.0,0,0.5
Retrograde transport at the Trans_Golgi_Network,100,-0.0,0.0,0.0,0,0.5
COPI_dependent Golgi_to_ER retrograde traffic,100,-0.0,0.0,0.0,0,0.5
Kinesins,100,-0.0,0.0,0.0,0,0.5
COPI_independent Golgi_to_ER retrograde traffic,100,-0.0,0.0,0.0,0,0.5
COPI_mediated anterograde transport,100,-0.0,0.0,0.0,0,0.5
COPII Coat Protein 2 Mediated Vesicle Transport,100,-0.0,0.0,0.0,0,0.5
Cargo concentration in the ER,100,-0.0,0.0,0.0,0,0.5
Intraflagellar transport,100,-0.0,0.0,0.0,0,0.5
Antigen Presentation: Folding assembly and peptide loading of class I MHC,100,-0.0,0.0,0.0,0,0.5
N_glycan trimming in the ER and CalnexinslashCalreticulin cycle,100,-0.0,0.0,0.0,0,0.5
Calnexinslashcalreticulin cycle,100,-0.0,0.0,0.0,0,0.5
XBP1S activates chaperone genes,100,-0.0,0.0,0.0,0,0.5
IRE1alpha activates chaperones,100,-0.0,0.0,0.0,0,0.5
Unfolded Protein Response UPR,100,-0.0,0.0,0.0,0,0.5
PERK regulates gene expression,100,-0.0,0.0,0.0,0,0.5
ATF4 activates genes,100,-0.0,0.0,0.0,0,0.5
KSRP KHSRP binds and destabilizes mRNA,100,-0.0,0.0,0.0,0,0.5
Tristetraprolin TTP ZFP36 binds and destabilizes mRNA,100,-0.0,0.0,0.0,0,0.5
Butyrate Response Factor 1 BRF1 binds and destabilizes mRNA,100,-0.0,0.0,0.0,0,0.5
mRNA decay by 5  to 3  exoribonuclease,100,-0.0,0.0,0.0,0,0.5
Deadenylation_dependent mRNA decay,100,-0.0,0.0,0.0,0,0.5
Deadenylation of mRNA,100,-0.0,0.0,0.0,0,0.5
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,100,-0.0,0.0,0.0,0,0.5
TP53 Regulates Transcription of Cell Cycle Genes,100,-0.0,0.0,0.0,0,0.5
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,100,-0.0,0.0,0.0,0,0.5
TP53 Regulates Transcription of Cell Death Genes,1400,0.05999198285096348,0.09741986365147343,0.0,0,0.8013833545822916
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,100,-0.0,0.0,0.0,0,0.5
Intrinsic Pathway for Apoptosis,100,-0.0,0.0,0.0,0,0.5
Activation of BH3_only proteins,100,-0.0,0.0,0.0,0,0.5
Activation of BAD and translocation to mitochondria,100,-0.0,0.0,0.0,0,0.5
Translocation of GLUT4 to the plasma membrane,100,-0.0,0.0,0.0,0,0.5
TP53 Regulates Metabolic Genes,100,-0.0,0.0,0.0,0,0.5
PI3K Cascade,100,-0.0,0.0,0.0,0,0.5
mTORC1_mediated signalling,100,-0.0,0.0,0.0,0,0.5
PKB_mediated events,100,-0.0,0.0,0.0,0,0.5
mTOR signalling,100,-0.0,0.0,0.0,0,0.5
Energy dependent regulation of mTOR by LKB1_AMPK,100,-0.0,0.0,0.0,0,0.5
Macroautophagy,100,-0.0,0.0,0.0,0,0.5
PD_1 signaling,100,-0.0,0.0,0.0,0,0.5
Phosphorylation of CD3 and TCR zeta chains,100,-0.0,0.0,0.0,0,0.5
Translocation of ZAP_70 to Immunological synapse,100,-0.0,0.0,0.0,0,0.5
Generation of second messenger molecules,100,-0.0,0.0,0.0,0,0.5
Costimulation by the CD28 family,100,-0.0,0.0,0.0,0,0.5
CD28 co_stimulation,100,-0.0,0.0,0.0,0,0.5
CD28 dependent PI3KslashAkt signaling,100,-0.0,0.0,0.0,0,0.5
VEGFR2 mediated vascular permeability,100,-0.0,0.0,0.0,0,0.5
Constitutive Signaling by AKT1 E17K in Cancer,100,-0.0,0.0,0.0,0,0.5
Regulation of TP53 Activity through Acetylation,100,-0.0,0.0,0.0,0,0.5
Regulation of gene expression in beta cells,100,-0.0,0.0,0.0,0,0.5
Regulation of beta_cell development,100,-0.0,0.0,0.0,0,0.5
Regulation of innate immune responses to cytosolic DNA,100,-0.0,0.0,0.0,0,0.5
STING mediated induction of host immune responses,100,-0.0,0.0,0.0,0,0.5
HSF1 activation,1500,0.22989479564991924,0.31877866694510976,0.0,0,0.8369341450940667
Attenuation phase,1500,0.22989479564991924,0.22989479564991924,0.0,0,0.8369341450940667
HSF1_dependent transactivation,100,-0.0,0.0,0.0,0,0.5
Cellular response to heat stress,100,-0.0,0.0,0.0,0,0.5
Regulation of HSF1_mediated heat shock response,100,-0.0,0.0,0.0,0,0.5
SUMOylation of DNA damage response and repair proteins,100,-0.0,0.0,0.0,0,0.5
SUMO E3 ligases SUMOylate target proteins,100,-0.0,0.0,0.0,0,0.5
Transcriptional regulation by small RNAs,100,-0.0,0.0,0.0,0,0.5
Nuclear Envelope Breakdown,100,-0.0,0.0,0.0,0,0.5
Metabolism of non_coding RNA,100,-0.0,0.0,0.0,0,0.5
snRNP Assembly,100,-0.0,0.0,0.0,0,0.5
SUMOylation of RNA binding proteins,100,-0.0,0.0,0.0,0,0.5
Hexose transport,100,-0.0,0.0,0.0,0,0.5
Glucose transport,100,-0.0,0.0,0.0,0,0.5
SUMOylation of DNA replication proteins,100,-0.0,0.0,0.0,0,0.5
Viral Messenger RNA Synthesis,100,-0.0,0.0,0.0,0,0.5
Transport of Mature mRNA Derived from an Intronless Transcript,100,-0.0,0.0,0.0,0,0.5
Transport of Mature mRNAs Derived from Intronless Transcripts,100,-0.0,0.0,0.0,0,0.5
Transport of the SLBP Dependant Mature mRNA,100,-0.0,0.0,0.0,0,0.5
Transport of the SLBP independent Mature mRNA,100,-0.0,0.0,0.0,0,0.5
Nuclear Pore Complex NPC Disassembly,100,-0.0,0.0,0.0,0,0.5
Nuclear import of Rev protein,100,-0.0,0.0,0.0,0,0.5
Interactions of Rev with host cellular proteins,100,-0.0,0.0,0.0,0,0.5
Rev_mediated nuclear export of HIV RNA,100,-0.0,0.0,0.0,0,0.5
NEPslashNS2 Interacts with the Cellular Export Machinery,100,-0.0,0.0,0.0,0,0.5
Export of Viral Ribonucleoproteins from Nucleus,100,-0.0,0.0,0.0,0,0.5
Regulation of Glucokinase by Glucokinase Regulatory Protein,100,-0.0,0.0,0.0,0,0.5
Transport of Ribonucleoproteins into the Host Nucleus,100,-0.0,0.0,0.0,0,0.5
Vpr_mediated nuclear import of PICs,100,-0.0,0.0,0.0,0,0.5
Interactions of Vpr with host cellular proteins,100,-0.0,0.0,0.0,0,0.5
Host Interactions with Influenza Factors,100,-0.0,0.0,0.0,0,0.5
NS1 Mediated Effects on Host Pathways,100,-0.0,0.0,0.0,0,0.5
ISG15 antiviral mechanism,100,-0.0,0.0,0.0,0,0.5
Antiviral mechanism by IFN_stimulated genes,100,-0.0,0.0,0.0,0,0.5
tRNA processing in the nucleus,100,-0.0,0.0,0.0,0,0.5
Cleavage of Growing Transcript in the Termination Region,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II Transcription Termination,100,-0.0,0.0,0.0,0,0.5
Post_Elongation Processing of the Transcript,100,-0.0,0.0,0.0,0,0.5
mRNA 3 _end processing,100,-0.0,0.0,0.0,0,0.5
Post_Elongation Processing of Intron_Containing pre_mRNA,100,-0.0,0.0,0.0,0,0.5
Transport of Mature Transcript to Cytoplasm,100,-0.0,0.0,0.0,0,0.5
Transport of Mature mRNA derived from an Intron_Containing Transcript,100,-0.0,0.0,0.0,0,0.5
mRNA Splicing _ Minor Pathway,100,-0.0,0.0,0.0,0,0.5
Post_Elongation Processing of Intronless pre_mRNA,100,-0.0,0.0,0.0,0,0.5
Processing of Capped Intronless Pre_mRNA,100,-0.0,0.0,0.0,0,0.5
Processing of Intronless Pre_mRNAs,100,-0.0,0.0,0.0,0,0.5
rRNA modification in the nucleus,100,-0.0,0.0,0.0,0,0.5
Selenocysteine synthesis,100,-0.0,0.0,0.0,0,0.5
Viral mRNA Translation,100,-0.0,0.0,0.0,0,0.5
Peptide chain elongation,100,-0.0,0.0,0.0,0,0.5
Eukaryotic Translation Elongation,100,-0.0,0.0,0.0,0,0.5
Eukaryotic Translation Termination,100,-0.0,0.0,0.0,0,0.5
Nonsense Mediated Decay NMD independent of the Exon Junction Complex EJC,100,-0.0,0.0,0.0,0,0.5
Formation of a pool of free 40S subunits,100,-0.0,0.0,0.0,0,0.5
Formation of the ternary complex and subsequently the 43S complex,100,-0.0,0.0,0.0,0,0.5
Ribosomal scanning and start codon recognition,100,-0.0,0.0,0.0,0,0.5
Translation initiation complex formation,100,-0.0,0.0,0.0,0,0.5
Activation of the mRNA upon binding of the cap_binding complex and eIFs and subsequent binding to 43S,100,-0.0,0.0,0.0,0,0.5
Formation of Senescence_Associated Heterochromatin Foci SAHF,100,-0.0,0.0,0.0,0,0.5
DNA DamageslashTelomere Stress Induced Senescence,100,-0.0,0.0,0.0,0,0.5
Oxidative Stress Induced Senescence,100,-0.0,0.0,0.0,0,0.5
Senescence_Associated Secretory Phenotype SASP,100,-0.0,0.0,0.0,0,0.5
Amyloid fiber formation,100,-0.0,0.0,0.0,0,0.5
Deposition of new CENPA_containing nucleosomes at the centromere,100,-0.0,0.0,0.0,0,0.5
Nucleosome assembly,100,-0.0,0.0,0.0,0,0.5
Chromosome Maintenance,100,-0.0,0.0,0.0,0,0.5
Telomere Maintenance,100,-0.0,0.0,0.0,0,0.5
Meiotic recombination,100,-0.0,0.0,0.0,0,0.5
Meiosis,100,-0.0,0.0,0.0,0,0.5
Meiotic synapsis,100,-0.0,0.0,0.0,0,0.5
Packaging Of Telomere Ends,100,-0.0,0.0,0.0,0,0.5
SIRT1 negatively regulates rRNA Expression,100,-0.0,0.0,0.0,0,0.5
Activated PKN1 stimulates transcription of AR androgen receptor regulated genes KLK2 and KLK3,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase I Promoter Opening,100,-0.0,0.0,0.0,0,0.5
DNA methylation,100,-0.0,0.0,0.0,0,0.5
PRC2 methylates histones and DNA,100,-0.0,0.0,0.0,0,0.5
Condensation of Prophase Chromosomes,100,-0.0,0.0,0.0,0,0.5
ERCC6 CSB and EHMT2 G9a positively regulate rRNA expression,100,-0.0,0.0,0.0,0,0.5
RHO GTPases activate PKNs,100,-0.0,0.0,0.0,0,0.5
Formation of the beta_catenin:TCF transactivating complex,100,-0.0,0.0,0.0,0,0.5
Activation of anterior HOX genes in hindbrain development during early embryogenesis,100,-0.0,0.0,0.0,0,0.5
Activation of HOX genes during differentiation,100,-0.0,0.0,0.0,0,0.5
B_WICH complex positively regulates rRNA expression,100,-0.0,0.0,0.0,0,0.5
Positive epigenetic regulation of rRNA expression,100,-0.0,0.0,0.0,0,0.5
Negative epigenetic regulation of rRNA expression,100,-0.0,0.0,0.0,0,0.5
NoRC negatively regulates rRNA expression,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase I Chain Elongation,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase I Transcription,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase I Promoter Clearance,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase I Transcription Initiation,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase I Promoter Escape,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase I Transcription Termination,100,-0.0,0.0,0.0,0,0.5
RMTs methylate histone arginines,100,-0.0,0.0,0.0,0,0.5
HDACs deacetylate histones,100,-0.0,0.0,0.0,0,0.5
PKMTs methylate histone lysines,100,-0.0,0.0,0.0,0,0.5
HDMs demethylate histones,100,-0.0,0.0,0.0,0,0.5
Transcriptional regulation of pluripotent stem cells,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Transcription Termination,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Chain Elongation,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Transcription Initiation From Type 2 Promoter,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Transcription Initiation From Type 1 Promoter,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Abortive And Retractive Initiation,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Transcription,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Transcription Initiation,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase III Transcription Initiation From Type 3 Promoter,100,-0.0,0.0,0.0,0,0.5
RNA polymerase II transcribes snRNA genes,100,-0.0,0.0,0.0,0,0.5
PIWI_interacting RNA piRNA biogenesis,100,-0.0,0.0,0.0,0,0.5
MicroRNA miRNA biogenesis,100,-0.0,0.0,0.0,0,0.5
FGFR2 alternative splicing,100,-0.0,0.0,0.0,0,0.5
Signaling by FGFR2 IIIa TM,100,-0.0,0.0,0.0,0,0.5
Abortive elongation of HIV_1 transcript in the absence of Tat,100,-0.0,0.0,0.0,0,0.5
Formation of the Early Elongation Complex,100,-0.0,0.0,0.0,0,0.5
Formation of the HIV_1 Early Elongation Complex,100,-0.0,0.0,0.0,0,0.5
Formation of HIV elongation complex in the absence of HIV Tat,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II Transcription Elongation,100,-0.0,0.0,0.0,0,0.5
Formation of RNA Pol II elongation complex,100,-0.0,0.0,0.0,0,0.5
HIV Transcription Elongation,100,-0.0,0.0,0.0,0,0.5
Tat_mediated elongation of the HIV_1 transcript,100,-0.0,0.0,0.0,0,0.5
Formation of HIV_1 elongation complex containing HIV_1 Tat,100,-0.0,0.0,0.0,0,0.5
Pausing and recovery of Tat_mediated HIV elongation,100,-0.0,0.0,0.0,0,0.5
Tat_mediated HIV elongation arrest and recovery,100,-0.0,0.0,0.0,0,0.5
HIV elongation arrest and recovery,100,-0.0,0.0,0.0,0,0.5
Pausing and recovery of HIV elongation,100,-0.0,0.0,0.0,0,0.5
Elongation arrest and recovery,100,-0.0,0.0,0.0,0,0.5
TP53 Regulates Transcription of DNA Repair Genes,100,-0.0,0.0,0.0,0,0.5
Transcription of the HIV genome,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II Pre_transcription Events,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II HIV Promoter Escape,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II Promoter Escape,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II Transcription Initiation And Promoter Clearance,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II Transcription Initiation,100,-0.0,0.0,0.0,0,0.5
RNA Polymerase II Transcription Pre_Initiation And Promoter Opening,100,-0.0,0.0,0.0,0,0.5
HIV Transcription Initiation,100,-0.0,0.0,0.0,0,0.5
RNA Pol II CTD phosphorylation and interaction with CE,100,-0.0,0.0,0.0,0,0.5
mRNA Capping,100,-0.0,0.0,0.0,0,0.5
Formation of TC_NER Pre_Incision Complex,100,-0.0,0.0,0.0,0,0.5
Dual incision in TC_NER,100,-0.0,0.0,0.0,0,0.5
Gap_filling DNA repair synthesis and ligation in TC_NER,100,-0.0,0.0,0.0,0,0.5
Transcription_Coupled Nucleotide Excision Repair TC_NER,100,-0.0,0.0,0.0,0,0.5
Global Genome Nucleotide Excision Repair GG_NER,100,-0.0,0.0,0.0,0,0.5
Formation of Incision Complex in GG_NER,100,-0.0,0.0,0.0,0,0.5
DNA Damage Recognition in GG_NER,100,-0.0,0.0,0.0,0,0.5
Processing of DNA double_strand break ends,100,-0.0,0.0,0.0,0,0.5
G2slashM DNA damage checkpoint,100,-0.0,0.0,0.0,0,0.5
Nonhomologous End_Joining NHEJ,100,-0.0,0.0,0.0,0,0.5
Recruitment and ATM_mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,100,-0.0,0.0,0.0,0,0.5
DNA Double Strand Break Response,100,-0.0,0.0,0.0,0,0.5
HDR through Single Strand Annealing SSA,100,-0.0,0.0,0.0,0,0.5
Presynaptic phase of homologous DNA pairing and strand exchange,100,-0.0,0.0,0.0,0,0.5
Homologous DNA Pairing and Strand Exchange,100,-0.0,0.0,0.0,0,0.5
HDR through Homologous Recombination HRR,100,-0.0,0.0,0.0,0,0.5
Resolution of D_loop Structures through Holliday Junction Intermediates,100,-0.0,0.0,0.0,0,0.5
Resolution of D_Loop Structures,100,-0.0,0.0,0.0,0,0.5
Resolution of D_loop Structures through Synthesis_Dependent Strand Annealing SDSA,100,-0.0,0.0,0.0,0,0.5
Regulation of TP53 Activity through Phosphorylation,1200,0.030354360131868197,0.030354360131868197,0.0,0,0.7826882560257099
Regulation of TP53 Expression and Degradation,100,-0.0,0.0,0.0,0,0.5
Regulation of TP53 Degradation,100,-0.0,0.0,0.0,0,0.5
Regulation of TP53 Activity through Methylation,1200,0.4194086318997797,1.8152364112951664,0.0,0,0.8527283767403717
Translesion Synthesis by POLH,100,-0.0,0.0,0.0,0,0.5
Translesion synthesis by POLK,1200,0.0021198011474289477,0.0021198011474289477,0.0,0,0.7764651143557142
Translesion synthesis by REV1,1200,0.0021198011474289477,0.0021198011474289477,0.0,0,0.7764651143557142
Translesion synthesis by POLI,1200,0.0021198011474289477,0.0021198011474289477,0.0,0,0.7764651143557142
Termination of translesion DNA synthesis,750,0.18513620930179156,0.44397744756058327,0.0,0,0.7777274260121428
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,1200,0.030354360131868197,0.03703098371191776,0.0,0,0.7826882560257099
DNA Damage Bypass,1200,0.06024891403647658,0.08597212213897558,0.0,0,0.7890885500561515
Recognition of DNA damage by PCNA_containing replication complex,100,-0.0,0.0,0.0,0,0.5
Gap_filling DNA repair synthesis and ligation in GG_NER,100,-0.0,0.0,0.0,0,0.5
Dual Incision in GG_NER,100,-0.0,0.0,0.0,0,0.5
Base Excision Repair,100,-0.0,0.0,0.0,0,0.5
Resolution of Abasic Sites AP sites,100,-0.0,0.0,0.0,0,0.5
Resolution of AP sites via the multiple_nucleotide patch replacement pathway,100,-0.0,0.0,0.0,0,0.5
PCNA_Dependent Long Patch Base Excision Repair,100,-0.0,0.0,0.0,0,0.5
Extension of Telomeres,100,-0.0,0.0,0.0,0,0.5
Telomere C_strand Lagging Strand Synthesis,100,-0.0,0.0,0.0,0,0.5
Lagging Strand Synthesis,100,-0.0,0.0,0.0,0,0.5
DNA strand elongation,100,-0.0,0.0,0.0,0,0.5
Mismatch Repair,100,-0.0,0.0,0.0,0,0.5
Processive synthesis on the lagging strand,100,-0.0,0.0,0.0,0,0.5
E2F mediated regulation of DNA replication,100,-0.0,0.0,0.0,0,0.5
G1slashS_Specific Transcription,100,-0.0,0.0,0.0,0,0.5
Association of licensing factors with the pre_replicative complex,100,-0.0,0.0,0.0,0,0.5
Activation of ATR in response to replication stress,100,-0.0,0.0,0.0,0,0.5
Activation of the pre_replicative complex,100,-0.0,0.0,0.0,0,0.5
G0 and Early G1,100,-0.0,0.0,0.0,0,0.5
Signal transduction by L1,100,-0.0,0.0,0.0,0,0.5
RAF_independent MAPK1slash3 activation,100,-0.0,0.0,0.0,0,0.5
Interleukin_6 family signaling,100,-0.0,0.0,0.0,0,0.5
IL_6_type cytokine receptor ligand interactions,100,-0.0,0.0,0.0,0,0.5
Regulation of IFNA signaling,100,-0.0,0.0,0.0,0,0.5
Interferon alphaslashbeta signaling,1500,0.6581631276899017,0.7367542427374346,0.0,0,0.8937403311079215
Interferon gamma signaling,1500,0.08829645270888385,0.11244589136157372,0.0,0,0.8121295780992708
Growth hormone receptor signaling,1500,0.3884538171863646,0.8398624671789356,0.0,0,0.8608440682523557
Prolactin receptor signaling,100,-0.0,0.0,0.0,0,0.5
Nuclear signaling by ERBB4,100,-0.0,0.0,0.0,0,0.5
NOTCH1 Intracellular Domain Regulates Transcription,100,-0.0,0.0,0.0,0,0.5
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,100,-0.0,0.0,0.0,0,0.5
Signaling by NOTCH1 in Cancer,100,-0.0,0.0,0.0,0,0.5
Signaling by NOTCH1 PEST Domain Mutants in Cancer,100,-0.0,0.0,0.0,0,0.5
Constitutive Signaling by NOTCH1 PEST Domain Mutants,100,-0.0,0.0,0.0,0,0.5
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,100,-0.0,0.0,0.0,0,0.5
Signaling by NOTCH1,100,-0.0,0.0,0.0,0,0.5
Constitutive Signaling by NOTCH1 HD Domain Mutants,100,-0.0,0.0,0.0,0,0.5
Signaling by NOTCH1 HD Domain Mutants in Cancer,100,-0.0,0.0,0.0,0,0.5
Activated NOTCH1 Transmits Signal to the Nucleus,100,-0.0,0.0,0.0,0,0.5
NOTCH2 Activation and Transmission of Signal to the Nucleus,100,-0.0,0.0,0.0,0,0.5
Signaling by NOTCH2,100,-0.0,0.0,0.0,0,0.5
Pre_NOTCH Transcription and Translation,100,-0.0,0.0,0.0,0,0.5
Pre_NOTCH Expression and Processing,100,-0.0,0.0,0.0,0,0.5
Pre_NOTCH Processing in Golgi,100,-0.0,0.0,0.0,0,0.5
NRIF signals cell death from the nucleus,100,-0.0,0.0,0.0,0,0.5
p75NTR signals via NF_kB,100,-0.0,0.0,0.0,0,0.5
TRAF6 mediated induction of TAK1 complex,900,0.29976109115315464,1.0847254735560456,0.0,0,0.8147511925369426
Budding and maturation of HIV virion,100,-0.0,0.0,0.0,0,0.5
Endosomal Sorting Complex Required For Transport ESCRT,100,-0.0,0.0,0.0,0,0.5
PinkslashParkin Mediated Mitophagy,100,-0.0,0.0,0.0,0,0.5
Mitophagy,100,-0.0,0.0,0.0,0,0.5
Fanconi Anemia Pathway,100,-0.0,0.0,0.0,0,0.5
Oncogene Induced Senescence,100,-0.0,0.0,0.0,0,0.5
G1 Phase,100,-0.0,0.0,0.0,0,0.5
Cyclin D associated events in G1,100,-0.0,0.0,0.0,0,0.5
SMAD2slashSMAD3:SMAD4 heterotrimer regulates transcription,100,-0.0,0.0,0.0,0,0.5
Transcriptional activity of SMAD2slashSMAD3:SMAD4 heterotrimer,100,-0.0,0.0,0.0,0,0.5
Signaling by TGF_beta Receptor Complex,100,-0.0,0.0,0.0,0,0.5
Downregulation of SMAD2slash3:SMAD4 transcriptional activity,100,-0.0,0.0,0.0,0,0.5
Oxygen_dependent proline hydroxylation of Hypoxia_inducible Factor Alpha,100,-0.0,0.0,0.0,0,0.5
Regulation of Hypoxia_inducible Factor HIF by oxygen,100,-0.0,0.0,0.0,0,0.5
Cellular response to hypoxia,100,-0.0,0.0,0.0,0,0.5
Glycogen synthesis,100,-0.0,0.0,0.0,0,0.5
Glycogen breakdown glycogenolysis,100,-0.0,0.0,0.0,0,0.5
Glucose metabolism,100,-0.0,0.0,0.0,0,0.5
Gluconeogenesis,100,-0.0,0.0,0.0,0,0.5
Glycolysis,100,-0.0,0.0,0.0,0,0.5
DARPP_32 events,100,-0.0,0.0,0.0,0,0.5
Negative regulation of MAPK pathway,100,-0.0,0.0,0.0,0,0.5
RAF activation,100,-0.0,0.0,0.0,0,0.5
CTLA4 inhibitory signaling,100,-0.0,0.0,0.0,0,0.5
Platelet sensitization by LDL,100,-0.0,0.0,0.0,0,0.5
S33 mutants of beta_catenin aren t phosphorylated,100,-0.0,0.0,0.0,0,0.5
S45 mutants of beta_catenin aren t phosphorylated,100,-0.0,0.0,0.0,0,0.5
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex,100,-0.0,0.0,0.0,0,0.5
T41 mutants of beta_catenin aren t phosphorylated,100,-0.0,0.0,0.0,0,0.5
S37 mutants of beta_catenin aren t phosphorylated,100,-0.0,0.0,0.0,0,0.5
Misspliced GSK3beta mutants stabilize beta_catenin,100,-0.0,0.0,0.0,0,0.5
Beta_catenin phosphorylation cascade,100,-0.0,0.0,0.0,0,0.5
Disassembly of the destruction complex and recruitment of AXIN to the membrane,100,-0.0,0.0,0.0,0,0.5
Signaling by WNT in cancer,100,-0.0,0.0,0.0,0,0.5
Spry regulation of FGF signaling,100,-0.0,0.0,0.0,0,0.5
Negative regulation of FGFR4 signaling,100,-0.0,0.0,0.0,0,0.5
Negative regulation of FGFR3 signaling,100,-0.0,0.0,0.0,0,0.5
Negative regulation of FGFR2 signaling,100,-0.0,0.0,0.0,0,0.5
Negative regulation of FGFR1 signaling,100,-0.0,0.0,0.0,0,0.5
FGFR2 ligand binding and activation,100,-0.0,0.0,0.0,0,0.5
Activated point mutants of FGFR2,100,-0.0,0.0,0.0,0,0.5
FGFR1 ligand binding and activation,100,-0.0,0.0,0.0,0,0.5
SHC_mediated cascade:FGFR1,100,-0.0,0.0,0.0,0,0.5
SHC_mediated cascade:FGFR2,100,-0.0,0.0,0.0,0,0.5
SHC_mediated cascade:FGFR4,100,-0.0,0.0,0.0,0,0.5
SHC_mediated cascade:FGFR3,100,-0.0,0.0,0.0,0,0.5
Signaling by FGFR3 point mutants in cancer,100,-0.0,0.0,0.0,0,0.5
Signaling by FGFR3 in disease,100,-0.0,0.0,0.0,0,0.5
FGFR2 mutant receptor activation,100,-0.0,0.0,0.0,0,0.5
Signaling by FGFR2 in disease,100,-0.0,0.0,0.0,0,0.5
Signaling by FGFR in disease,100,-0.0,0.0,0.0,0,0.5
Signaling by FGFR1 in disease,100,-0.0,0.0,0.0,0,0.5
FGFR1 mutant receptor activation,100,-0.0,0.0,0.0,0,0.5
Signaling by cytosolic FGFR1 fusion mutants,100,-0.0,0.0,0.0,0,0.5
PI3KslashAKT Signaling in Cancer,100,-0.0,0.0,0.0,0,0.5
Constitutive Signaling by Aberrant PI3K in Cancer,100,-0.0,0.0,0.0,0,0.5
PI5P PP2A and IER3 Regulate PI3KslashAKT Signaling,100,-0.0,0.0,0.0,0,0.5
Negative regulation of the PI3KslashAKT network,100,-0.0,0.0,0.0,0,0.5
CLEC7A Dectin_1 signaling,100,-0.0,0.0,0.0,0,0.5
Downstream TCR signaling,100,-0.0,0.0,0.0,0,0.5
Metabolism of polyamines,100,-0.0,0.0,0.0,0,0.5
Hedgehog  on  state,100,-0.0,0.0,0.0,0,0.5
Hedgehog  off  state,100,-0.0,0.0,0.0,0,0.5
TNFR2 non_canonical NF_kB pathway,100,-0.0,0.0,0.0,0,0.5
Degradation of beta_catenin by the destruction complex,100,-0.0,0.0,0.0,0,0.5
Antigen processing_Cross presentation,100,-0.0,0.0,0.0,0,0.5
ER_Phagosome pathway,100,-0.0,0.0,0.0,0,0.5
Autodegradation of Cdh1 by Cdh1:APCslashC,100,-0.0,0.0,0.0,0,0.5
APCslashC:Cdc20 mediated degradation of Securin,100,-0.0,0.0,0.0,0,0.5
APCslashC:Cdh1 mediated degradation of Cdc20 and other APCslashC:Cdh1 targeted proteins in late mitosisslashearly G1,100,-0.0,0.0,0.0,0,0.5
APCslashC_mediated degradation of cell cycle proteins,100,-0.0,0.0,0.0,0,0.5
Regulation of mitotic cell cycle,100,-0.0,0.0,0.0,0,0.5
Regulation of APCslashC activators between G1slashS and early anaphase,100,-0.0,0.0,0.0,0,0.5
Activation of APCslashC and APCslashC:Cdc20 mediated degradation of mitotic proteins,100,-0.0,0.0,0.0,0,0.5
APCslashC:Cdc20 mediated degradation of mitotic proteins,100,-0.0,0.0,0.0,0,0.5
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint,100,-0.0,0.0,0.0,0,0.5
Cdc20:Phospho_APCslashC mediated degradation of Cyclin A,100,-0.0,0.0,0.0,0,0.5
Regulation of RAS by GAPs,100,-0.0,0.0,0.0,0,0.5
Activation of NF_kappaB in B cells,100,-0.0,0.0,0.0,0,0.5
Dectin_1 mediated noncanonical NF_kB signaling,100,-0.0,0.0,0.0,0,0.5
NIK__>noncanonical NF_kB signaling,100,-0.0,0.0,0.0,0,0.5
Degradation of GLI1 by the proteasome,100,-0.0,0.0,0.0,0,0.5
GLI3 is processed to GLI3R by the proteasome,100,-0.0,0.0,0.0,0,0.5
Degradation of GLI2 by the proteasome,100,-0.0,0.0,0.0,0,0.5
SCF_beta_TrCP mediated degradation of Emi1,100,-0.0,0.0,0.0,0,0.5
Vpu mediated degradation of CD4,100,-0.0,0.0,0.0,0,0.5
CDK_mediated phosphorylation and removal of Cdc6,100,-0.0,0.0,0.0,0,0.5
Ubiquitin_dependent degradation of Cyclin D1,100,-0.0,0.0,0.0,0,0.5
Ubiquitin_dependent degradation of Cyclin D,100,-0.0,0.0,0.0,0,0.5
Regulation of activated PAK_2p34 by proteasome mediated degradation,100,-0.0,0.0,0.0,0,0.5
Regulation of Apoptosis,100,-0.0,0.0,0.0,0,0.5
Autodegradation of the E3 ubiquitin ligase COP1,100,-0.0,0.0,0.0,0,0.5
Stabilization of p53,100,-0.0,0.0,0.0,0,0.5
p53_Independent DNA Damage Response,100,-0.0,0.0,0.0,0,0.5
p53_Independent G1slashS DNA damage checkpoint,100,-0.0,0.0,0.0,0,0.5
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A,100,-0.0,0.0,0.0,0,0.5
Vif_mediated degradation of APOBEC3G,100,-0.0,0.0,0.0,0,0.5
AUF1 hnRNP D0 binds and destabilizes mRNA,100,-0.0,0.0,0.0,0,0.5
Degradation of AXIN,100,-0.0,0.0,0.0,0,0.5
Degradation of DVL,100,-0.0,0.0,0.0,0,0.5
Hh mutants that don t undergo autocatalytic processing are degraded by ERAD,100,-0.0,0.0,0.0,0,0.5
Hh mutants abrogate ligand secretion,100,-0.0,0.0,0.0,0,0.5
Hedgehog ligand biogenesis,100,-0.0,0.0,0.0,0,0.5
The role of GTSE1 in G2slashM progression after G2 checkpoint,100,-0.0,0.0,0.0,0,0.5
Cross_presentation of soluble exogenous antigens endosomes,100,-0.0,0.0,0.0,0,0.5
Regulation of ornithine decarboxylase ODC,100,-0.0,0.0,0.0,0,0.5
G1slashS DNA Damage Checkpoints,100,-0.0,0.0,0.0,0,0.5
p53_Dependent G1slashS DNA damage checkpoint,100,-0.0,0.0,0.0,0,0.5
p53_Dependent G1 DNA Damage Response,100,-0.0,0.0,0.0,0,0.5
SCFSkp2_mediated degradation of p27slashp21,100,-0.0,0.0,0.0,0,0.5
Cyclin A:Cdk2_associated events at S phase entry,100,-0.0,0.0,0.0,0,0.5
Cyclin E associated events during G1slashS transition,100,-0.0,0.0,0.0,0,0.5
Synthesis of DNA,100,-0.0,0.0,0.0,0,0.5
DNA Replication Pre_Initiation,100,-0.0,0.0,0.0,0,0.5
MslashG1 Transition,100,-0.0,0.0,0.0,0,0.5
Regulation of DNA replication,100,-0.0,0.0,0.0,0,0.5
Removal of licensing factors from origins,100,-0.0,0.0,0.0,0,0.5
Switching of origins to a post_replicative state,100,-0.0,0.0,0.0,0,0.5
Orc1 removal from chromatin,100,-0.0,0.0,0.0,0,0.5
Assembly of the pre_replicative complex,100,-0.0,0.0,0.0,0,0.5
CDT1 association with the CDC6:ORC:origin complex,100,-0.0,0.0,0.0,0,0.5
Regulation of mRNA stability by proteins that bind AU_rich elements,100,-0.0,0.0,0.0,0,0.5
MAPK6slashMAPK4 signaling,100,-0.0,0.0,0.0,0,0.5
Asymmetric localization of PCP proteins,100,-0.0,0.0,0.0,0,0.5
PCPslashCE pathway,100,-0.0,0.0,0.0,0,0.5
Deactivation of the beta_catenin transactivating complex,100,-0.0,0.0,0.0,0,0.5
APCslashC:Cdc20 mediated degradation of Cyclin B,100,-0.0,0.0,0.0,0,0.5
Phosphorylation of the APCslashC,100,-0.0,0.0,0.0,0,0.5
Conversion from APCslashC:Cdc20 to APCslashC:Cdh1 in late anaphase,100,-0.0,0.0,0.0,0,0.5
Mitotic Spindle Checkpoint,100,-0.0,0.0,0.0,0,0.5
Inhibition of the proteolytic activity of APCslashC required for the onset of anaphase by mitotic spindle checkpoint components,100,-0.0,0.0,0.0,0,0.5
Inactivation of APCslashC via direct inhibition of the APCslashC complex,100,-0.0,0.0,0.0,0,0.5
APC_Cdc20 mediated degradation of Nek2A,100,-0.0,0.0,0.0,0,0.5
Resolution of Sister Chromatid Cohesion,100,-0.0,0.0,0.0,0,0.5
PTK6 Regulates RHO GTPases RAS GTPase and MAP kinases,100,-0.0,0.0,0.0,0,0.5
Signaling by PTK6,100,-0.0,0.0,0.0,0,0.5
ERBB2 Regulates Cell Motility,100,-0.0,0.0,0.0,0,0.5
PI3K events in ERBB2 signaling,100,-0.0,0.0,0.0,0,0.5
GRB2 events in ERBB2 signaling,100,-0.0,0.0,0.0,0,0.5
SHC1 events in ERBB2 signaling,100,-0.0,0.0,0.0,0,0.5
Signaling by ERBB2,100,-0.0,0.0,0.0,0,0.5
Constitutive Signaling by Ligand_Responsive EGFR Cancer Variants,100,-0.0,0.0,0.0,0,0.5
Signaling by Ligand_Responsive EGFR Variants in Cancer,100,-0.0,0.0,0.0,0,0.5
Signaling by EGFR in Cancer,100,-0.0,0.0,0.0,0,0.5
Signaling by EGFRvIII in Cancer,100,-0.0,0.0,0.0,0,0.5
Constitutive Signaling by EGFRvIII,100,-0.0,0.0,0.0,0,0.5
Tie2 Signaling,100,-0.0,0.0,0.0,0,0.5
TRAF6 mediated IRF7 activation,100,-0.0,0.0,0.0,0,0.5
RIG_IslashMDA5 mediated induction of IFN_alphaslashbeta pathways,100,-0.0,0.0,0.0,0,0.5
Negative regulators of RIG_IslashMDA5 signaling,100,-0.0,0.0,0.0,0,0.5
Diseases associated with the TLR signaling cascade,950,0.7067543167878418,7.275511161875145,0.034482758620689655,950,0.8791725870328108
Diseases of Immune System,950,0.7067543167878418,7.275511161875145,0.034482758620689655,950,0.8791725870328108
Cytosolic sensors of pathogen_associated DNA,100,-0.0,0.0,0.0,0,0.5
ZBP1DAI mediated induction of type I IFNs,100,-0.0,0.0,0.0,0,0.5
RIP_mediated NFkB activation via ZBP1,100,-0.0,0.0,0.0,0,0.5
TRAF6 mediated NF_kB activation,950,0.0410802519636159,0.0410802519636159,0.0,0,0.7648938173597957
TAK1 activates NFkB by phosphorylation and activation of IKKs complex,100,-0.0,0.0,0.0,0,0.5
JNK c_Jun kinases phosphorylation and  activation mediated by activated human TAK1,100,-0.0,0.0,0.0,0,0.5
activated TAK1 mediates p38 MAPK activation,100,-0.0,0.0,0.0,0,0.5
NOD1slash2 Signaling Pathway,650,0.3399352039292808,1.6741685765146472,0.0,0,0.7994606317635662
Nucleotide_binding domain leucine rich repeat containing receptor NLR signaling pathways,700,0.7224503410523735,9.232115079953601,0.06896551724137931,700,0.866814556020219
Interleukin_1 signaling,650,0.40851982925323316,3.0633408274171257,0.0,0,0.81275349591409
MAP3K8 TPL2_dependent MAPK1slash3 activation,100,-0.0,0.0,0.0,0,0.5
MyD88_independent TLR3slashTLR4 cascade,950,0.0410802519636159,0.0410802519636159,0.0,0,0.7648938173597957
Toll Like Receptor 3 TLR3 Cascade,950,0.0410802519636159,0.0410802519636159,0.0,0,0.7648938173597957
TRIF_mediated TLR3slashTLR4 signaling,950,0.0410802519636159,0.0410802519636159,0.0,0,0.7648938173597957
MyD88:Mal cascade initiated on plasma membrane,950,0.7067543167878418,5.197451353997278,0.034482758620689655,950,0.8791725870328108
Toll Like Receptor TLR1:TLR2 Cascade,950,0.7067543167878418,5.197451353997278,0.034482758620689655,950,0.8791725870328108
Toll Like Receptor TLR6:TLR2 Cascade,950,0.7067543167878418,5.197451353997278,0.034482758620689655,950,0.8791725870328108
Toll Like Receptor 2 TLR2 Cascade,950,0.7067543167878418,5.197451353997278,0.034482758620689655,950,0.8791725870328108
Toll Like Receptor 9 TLR9 Cascade,100,-0.0,0.0,0.0,0,0.5
MyD88 dependent cascade initiated on endosome,100,-0.0,0.0,0.0,0,0.5
Toll Like Receptor 7slash8 TLR7slash8 Cascade,100,-0.0,0.0,0.0,0,0.5
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7slash8 or 9 activation,100,-0.0,0.0,0.0,0,0.5
Toll Like Receptor 10 TLR10 Cascade,950,0.0842184024665972,0.09167739645637239,0.0,0,0.774820220622491
Toll Like Receptor 5 TLR5 Cascade,950,0.0842184024665972,0.09167739645637239,0.0,0,0.774820220622491
MyD88 cascade initiated on plasma membrane,950,0.0842184024665972,0.09167739645637239,0.0,0,0.774820220622491
TRAF6 Mediated Induction of proinflammatory cytokines,100,-0.0,0.0,0.0,0,0.5
MAP kinase activation in TLR cascade,100,-0.0,0.0,0.0,0,0.5
MAPK targetsslash Nuclear events mediated by MAP kinases,100,-0.0,0.0,0.0,0,0.5
Nuclear Events kinase and transcription factor activation,100,-0.0,0.0,0.0,0,0.5
ERKslashMAPK targets,100,-0.0,0.0,0.0,0,0.5
Activation of IRF3slashIRF7 mediated by TBK1slashIKK epsilon,900,0.24219543564612206,0.77430423081205,0.0,0,0.8037743088544507
IKK complex recruitment mediated by RIP1,950,0.02898752571521649,0.056761088484271256,0.0,0,0.762033482889391
Caspase activation via extrinsic apoptotic signalig pathway,1250,0.0066766235800495575,0.0066766235800495575,0.0,0,0.7809859575186533
Ligand_dependent caspase activation,1250,0.3469609112599105,1.3840345281394009,0.0,0,0.8441566149460545
Regulated Necrosis,100,-0.0,0.0,0.0,0,0.5
RIPK1_mediated regulated necrosis,100,-0.0,0.0,0.0,0,0.5
TNFR1_induced NFkappaB signaling pathway,100,-0.0,0.0,0.0,0,0.5
Regulation of TNFR1 signaling,100,-0.0,0.0,0.0,0,0.5
TNF signaling,100,-0.0,0.0,0.0,0,0.5
Death Receptor Signalling,100,-0.0,0.0,0.0,0,0.5
Anchoring of the basal body to the plasma membrane,750,0.2738184928768169,0.6308777500316116,0.0,0,0.7965903032239234
Centrosome maturation,750,0.40463908006904387,1.4507856859965629,0.0,0,0.8215333821796913
Recruitment of mitotic centrosome proteins and complexes,750,0.40463908006904387,1.4507856859965629,0.0,0,0.8215333821796913
Loss of Nlp from mitotic centrosomes,750,0.460298780269238,1.9082074879399213,0.0,0,0.8311953940002875
Loss of proteins required for interphase microtubule organizationÂ from the centrosome,750,0.460298780269238,1.9082074879399213,0.0,0,0.8311953940002875
AURKA Activation by TPX2,750,0.460298780269238,1.8366490527982804,0.0,0,0.8311953940002875
Regulation of PLK1 Activity at G2slashM Transition,750,0.460298780269238,2.5289326155528054,0.0,0,0.8311953940002875
Polo_like kinase mediated events,100,-0.0,0.0,0.0,0,0.5
Cyclin AslashB1 associated events during G2slashM transition,100,-0.0,0.0,0.0,0,0.5
WNT ligand biogenesis and trafficking,100,-0.0,0.0,0.0,0,0.5
Negative regulation of TCF_dependent signaling by WNT ligand antagonists,100,-0.0,0.0,0.0,0,0.5
Regulation of FZD by ubiquitination,100,-0.0,0.0,0.0,0,0.5
Adherens junctions interactions,100,-0.0,0.0,0.0,0,0.5
Cell_cell junction organization,700,0.020385376178069875,0.05448504861762892,0.0,0,0.7312430505360428
Cell junction organization,100,-0.0,0.0,0.0,0,0.5
Tight junction interactions,100,-0.0,0.0,0.0,0,0.5
Cell_extracellular matrix interactions,100,-0.0,0.0,0.0,0,0.5
Basigin interactions,100,-0.0,0.0,0.0,0,0.5
Nephrin interactions,100,-0.0,0.0,0.0,0,0.5
Netrin_1 signaling,100,-0.0,0.0,0.0,0,0.5
Regulation of KIT signaling,100,-0.0,0.0,0.0,0,0.5
CD209 DC_SIGN signaling,100,-0.0,0.0,0.0,0,0.5
Rap1 signalling,100,-0.0,0.0,0.0,0,0.5
MAP2K and MAPK activation,100,-0.0,0.0,0.0,0,0.5
GRB2:SOS provides linkage to MAPK signaling for Integrins,100,-0.0,0.0,0.0,0,0.5
p130Cas linkage to MAPK signaling for integrins,100,-0.0,0.0,0.0,0,0.5
Integrin alphaIIb beta3 signaling,100,-0.0,0.0,0.0,0,0.5
Platelet Aggregation Plug Formation,100,-0.0,0.0,0.0,0,0.5
Other semaphorin interactions,100,-0.0,0.0,0.0,0,0.5
Semaphorin interactions,100,-0.0,0.0,0.0,0,0.5
CRMPs in Sema3A signaling,100,-0.0,0.0,0.0,0,0.5
Sema3A PAK dependent Axon repulsion,100,-0.0,0.0,0.0,0,0.5
Ephrin signaling,100,-0.0,0.0,0.0,0,0.5
EPHB_mediated forward signaling,100,-0.0,0.0,0.0,0,0.5
EPH_Ephrin signaling,100,-0.0,0.0,0.0,0,0.5
EPH_ephrin mediated repulsion of cells,100,-0.0,0.0,0.0,0,0.5
EPHA_mediated growth cone collapse,100,-0.0,0.0,0.0,0,0.5
RHO GTPases activate PAKs,100,-0.0,0.0,0.0,0,0.5
RHO GTPases activate CIT,100,-0.0,0.0,0.0,0,0.5
RHO GTPases Activate ROCKs,100,-0.0,0.0,0.0,0,0.5
Sema4D induced cell migration and growth_cone collapse,100,-0.0,0.0,0.0,0,0.5
Sema4D in semaphorin signaling,100,-0.0,0.0,0.0,0,0.5
Signaling by Robo receptor,100,-0.0,0.0,0.0,0,0.5
Myogenesis,100,-0.0,0.0,0.0,0,0.5
CDO in myogenesis,100,-0.0,0.0,0.0,0,0.5
RHO GTPases Activate WASPs and WAVEs,100,-0.0,0.0,0.0,0,0.5
Regulation of actin dynamics for phagocytic cup formation,100,-0.0,0.0,0.0,0,0.5
Role of phospholipids in phagocytosis,100,-0.0,0.0,0.0,0,0.5
FCGR activation,100,-0.0,0.0,0.0,0,0.5
Classical antibody_mediated complement activation,100,-0.0,0.0,0.0,0,0.5
Creation of C4 and C2 activators,100,-0.0,0.0,0.0,0,0.5
Initial triggering of complement,100,-0.0,0.0,0.0,0,0.5
Complement cascade,1150,0.4974262681961858,5.720229132544361,0.0,0,0.8615188181922231
Binding and Uptake of Ligands by Scavenger Receptors,100,-0.0,0.0,0.0,0,0.5
Scavenging of heme from plasma,100,-0.0,0.0,0.0,0,0.5
FCERI mediated Ca+2 mobilization,100,-0.0,0.0,0.0,0,0.5
CD22 mediated BCR regulation,100,-0.0,0.0,0.0,0,0.5
Antigen activates B Cell Receptor BCR leading to generation of second messengers,100,-0.0,0.0,0.0,0,0.5
Regulation of Complement cascade,700,0.7224503410523735,9.546639525773136,0.06896551724137931,700,0.866814556020219
Metabolism of Angiotensinogen to Angiotensins,100,-0.0,0.0,0.0,0,0.5
Regulation of Insulin_like Growth Factor IGF transport and uptake by Insulin_like Growth Factor Binding Proteins IGFBPs,100,-0.0,0.0,0.0,0,0.5
Synthesis secretion and inactivation of Glucagon_like Peptide_1 GLP_1,100,-0.0,0.0,0.0,0,0.5
Incretin synthesis secretion and inactivation,100,-0.0,0.0,0.0,0,0.5
Synthesis secretion and deacylation of Ghrelin,100,-0.0,0.0,0.0,0,0.5
Peptide hormone metabolism,100,-0.0,0.0,0.0,0,0.5
Insulin processing,100,-0.0,0.0,0.0,0,0.5
VxPx cargo_targeting to cilium,100,-0.0,0.0,0.0,0,0.5
Cargo trafficking to the periciliary membrane,100,-0.0,0.0,0.0,0,0.5
BBSome_mediated cargo_targeting to cilium,100,-0.0,0.0,0.0,0,0.5
Cooperation of PDCL PhLP1 and TRiCslashCCT in G_protein beta folding,100,-0.0,0.0,0.0,0,0.5
Chaperonin_mediated protein folding,100,-0.0,0.0,0.0,0,0.5
Association of TriCslashCCT with target proteins during biosynthesis,100,-0.0,0.0,0.0,0,0.5
Prefoldin mediated transfer of substrate  to CCTslashTriC,100,-0.0,0.0,0.0,0,0.5
Cooperation of Prefoldin and TriCslashCCT  in actin and tubulin folding,750,0.18513620930179156,0.41686191438416964,0.0,0,0.7777274260121428
Formation of tubulin folding intermediates by CCTslashTriC,750,0.40463908006904387,2.826600372629277,0.0,0,0.8215333821796913
Post_chaperonin tubulin folding pathway,950,0.7067543167878418,7.321193398441713,0.034482758620689655,950,0.8791725870328108
Regulation of signaling by CBL,100,-0.0,0.0,0.0,0,0.5
GPVI_mediated activation cascade,100,-0.0,0.0,0.0,0,0.5
G beta:gamma signalling through PI3Kgamma,100,-0.0,0.0,0.0,0,0.5
G_protein beta:gamma signalling,100,-0.0,0.0,0.0,0,0.5
Class Bslash2 Secretin family receptors,100,-0.0,0.0,0.0,0,0.5
Ca2+ pathway,100,-0.0,0.0,0.0,0,0.5
Activation of Kainate Receptors upon glutamate binding,100,-0.0,0.0,0.0,0,0.5
Presynaptic function of Kainate receptors,100,-0.0,0.0,0.0,0,0.5
G beta:gamma signalling through PLC beta,100,-0.0,0.0,0.0,0,0.5
Prostacyclin signalling through prostacyclin receptor,100,-0.0,0.0,0.0,0,0.5
ADP signalling through P2Y purinoceptor 12,100,-0.0,0.0,0.0,0,0.5
G_protein activation,100,-0.0,0.0,0.0,0,0.5
Adrenalinenoradrenaline inhibits insulin secretion,100,-0.0,0.0,0.0,0,0.5
Signal amplification,100,-0.0,0.0,0.0,0,0.5
ADP signalling through P2Y purinoceptor 1,100,-0.0,0.0,0.0,0,0.5
Thromboxane signalling through TP receptor,100,-0.0,0.0,0.0,0,0.5
Thrombin signalling through proteinase activated receptors PARs,100,-0.0,0.0,0.0,0,0.5
Glucagon_type ligand receptors,100,-0.0,0.0,0.0,0,0.5
Glucagon_like Peptide_1 GLP1 regulates insulin secretion,100,-0.0,0.0,0.0,0,0.5
Regulation of insulin secretion,100,-0.0,0.0,0.0,0,0.5
Opioid Signalling,100,-0.0,0.0,0.0,0,0.5
Glucagon signaling in metabolic regulation,100,-0.0,0.0,0.0,0,0.5
Vasopressin regulates renal water homeostasis via Aquaporins,100,-0.0,0.0,0.0,0,0.5
Aquaporin_mediated transport,100,-0.0,0.0,0.0,0,0.5
G alpha z signalling events,100,-0.0,0.0,0.0,0,0.5
GABA receptor activation,100,-0.0,0.0,0.0,0,0.5
GABA B receptor activation,100,-0.0,0.0,0.0,0,0.5
Activation of GABAB receptors,100,-0.0,0.0,0.0,0,0.5
Activation of G protein gated Potassium channels,100,-0.0,0.0,0.0,0,0.5
Inhibition  of voltage gated Ca2+ channels via Gbetaslashgamma subunits,100,-0.0,0.0,0.0,0,0.5
G protein gated Potassium channels,100,-0.0,0.0,0.0,0,0.5
Inwardly rectifying K+ channels,100,-0.0,0.0,0.0,0,0.5
Potassium Channels,100,-0.0,0.0,0.0,0,0.5
Voltage gated Potassium channels,100,-0.0,0.0,0.0,0,0.5
Activation of NMDA receptor upon glutamate binding and postsynaptic events,100,-0.0,0.0,0.0,0,0.5
Post NMDA receptor activation events,100,-0.0,0.0,0.0,0,0.5
CREB phosphorylation through the activation of Ras,100,-0.0,0.0,0.0,0,0.5
Ras activation uopn Ca2+ infux through NMDA receptor,100,-0.0,0.0,0.0,0,0.5
CREB phosphorylation through the activation of CaMKII,100,-0.0,0.0,0.0,0,0.5
Unblocking of NMDA receptor glutamate binding and activation,100,-0.0,0.0,0.0,0,0.5
SALM protein interactions at the synapse,100,-0.0,0.0,0.0,0,0.5
Phospholipase C_mediated cascade: FGFR1,100,-0.0,0.0,0.0,0,0.5
Phospholipase C_mediated cascade FGFR2,100,-0.0,0.0,0.0,0,0.5
Phospholipase C_mediated cascade FGFR3,100,-0.0,0.0,0.0,0,0.5
Phospholipase C_mediated cascade FGFR4,100,-0.0,0.0,0.0,0,0.5
EGFR interacts with phospholipase C_gamma,100,-0.0,0.0,0.0,0,0.5
DAG and IP3 signaling,100,-0.0,0.0,0.0,0,0.5
PLC_gamma1 signalling,100,-0.0,0.0,0.0,0,0.5
CaM pathway,100,-0.0,0.0,0.0,0,0.5
Calmodulin induced events,100,-0.0,0.0,0.0,0,0.5
Ca_dependent events,100,-0.0,0.0,0.0,0,0.5
PLC beta mediated events,100,-0.0,0.0,0.0,0,0.5
G_protein mediated events,100,-0.0,0.0,0.0,0,0.5
PKA_mediated phosphorylation of CREB,100,-0.0,0.0,0.0,0,0.5
PKA activation,100,-0.0,0.0,0.0,0,0.5
PKA activation in glucagon signalling,100,-0.0,0.0,0.0,0,0.5
The phototransduction cascade,100,-0.0,0.0,0.0,0,0.5
Inactivation recovery and regulation of the phototransduction cascade,100,-0.0,0.0,0.0,0,0.5
Smooth Muscle Contraction,100,-0.0,0.0,0.0,0,0.5
Striated Muscle Contraction,100,-0.0,0.0,0.0,0,0.5
Ion homeostasis,1150,0.4974262681961858,3.8812332026510936,0.0,0,0.8615188181922231
Ion transport by P_type ATPases,1500,0.22989479564991924,0.6193994944428495,0.0,0,0.8369341450940667
Platelet calcium homeostasis,100,-0.0,0.0,0.0,0,0.5
Elevation of cytosolic Ca2+ levels,100,-0.0,0.0,0.0,0,0.5
Platelet homeostasis,100,-0.0,0.0,0.0,0,0.5
Nitric oxide stimulates guanylate cyclase,100,-0.0,0.0,0.0,0,0.5
cGMP effects,100,-0.0,0.0,0.0,0,0.5
Phase 2 _ plateau phase,100,-0.0,0.0,0.0,0,0.5
Phase 1 _ inactivation of fast Na+ channels,100,-0.0,0.0,0.0,0,0.5
Phase 0 _ rapid depolarisation,100,-0.0,0.0,0.0,0,0.5
NCAM1 interactions,100,-0.0,0.0,0.0,0,0.5
Class Cslash3 Metabotropic glutamateslashpheromone receptors,100,-0.0,0.0,0.0,0,0.5
Chemokine receptors bind chemokines,100,-0.0,0.0,0.0,0,0.5
Nucleotide_like purinergic receptors,100,-0.0,0.0,0.0,0,0.5
Eicosanoid ligand_binding receptors,100,-0.0,0.0,0.0,0,0.5
Amine ligand_binding receptors,100,-0.0,0.0,0.0,0,0.5
eNOS activation and regulation,100,-0.0,0.0,0.0,0,0.5
Metabolism of nitric oxide,100,-0.0,0.0,0.0,0,0.5
Scavenging by Class A Receptors,100,-0.0,0.0,0.0,0,0.5
Chylomicron_mediated lipid transport,100,-0.0,0.0,0.0,0,0.5
Lipoprotein metabolism,100,-0.0,0.0,0.0,0,0.5
HDL_mediated lipid transport,100,-0.0,0.0,0.0,0,0.5
Lipid digestion mobilization and transport,750,0.460298780269238,4.4603133323114,0.0,0,0.8311953940002875
Hormone_sensitive lipase HSL_mediated triacylglycerol hydrolysis,750,0.460298780269238,4.082488314008605,0.0,0,0.8311953940002875
Digestion of dietary lipid,100,-0.0,0.0,0.0,0,0.5
Inositol phosphate metabolism,100,-0.0,0.0,0.0,0,0.5
Synthesis of IP3 and IP4 in the cytosol,100,-0.0,0.0,0.0,0,0.5
Synthesis of PIPs at the plasma membrane,100,-0.0,0.0,0.0,0,0.5
PI Metabolism,100,-0.0,0.0,0.0,0,0.5
Synthesis of PIPs at the Golgi membrane,100,-0.0,0.0,0.0,0,0.5
p75 NTR receptor_mediated signalling,950,0.7067543167878418,5.4651540448359945,0.034482758620689655,950,0.8791725870328108
Cell death signalling via NRAGE NRIF and NADE,950,0.6001699306496694,5.4417119091323345,0.0,0,0.8655829104452497
NRAGE signals death through JNK,850,0.3049817136332997,2.0551501805301298,0.0,0,0.8117376115390473
G alpha 12slash13 signalling events,100,-0.0,0.0,0.0,0,0.5
Signaling by Hippo,850,0.058433225574608255,0.1151943140588795,0.0,0,0.759099216709944
Apoptotic execution  phase,100,-0.0,0.0,0.0,0,0.5
Apoptotic cleavage of cellular proteins,100,-0.0,0.0,0.0,0,0.5
Mitochondrial protein import,100,-0.0,0.0,0.0,0,0.5
TGF_beta receptor signaling in EMT epithelial to mesenchymal transition,100,-0.0,0.0,0.0,0,0.5
TGF_beta receptor signaling activates SMADs,650,0.29178749412191046,1.2162905793335237,0.0,0,0.7895688991671563
Downregulation of TGF_beta receptor signaling,100,-0.0,0.0,0.0,0,0.5
Signaling by BMP,100,-0.0,0.0,0.0,0,0.5
Signaling by NODAL,750,0.010650068958108109,0.014462587752451926,0.0,0,0.7353546626883687
Inflammasomes,950,0.7067543167878418,11.240163421345562,0.034482758620689655,950,0.8791725870328108
Ligand_gated ion channel transport,100,-0.0,0.0,0.0,0,0.5
ROS RNS production in response to bacteria,100,-0.0,0.0,0.0,0,0.5
Insulin receptor recycling,100,-0.0,0.0,0.0,0,0.5
Transferrin endocytosis and recycling,950,0.0842184024665972,0.10925427168823179,0.0,0,0.774820220622491
Iron uptake and transport,950,0.06671622006973654,0.06671622006973654,0.0,0,0.7708443917015224
TRP channels,100,-0.0,0.0,0.0,0,0.5
Effects of PIP2 hydrolysis,100,-0.0,0.0,0.0,0,0.5
Synthesis of PC,100,-0.0,0.0,0.0,0,0.5
Synthesis of PA,100,-0.0,0.0,0.0,0,0.5
Acyl chain remodelling of PG,100,-0.0,0.0,0.0,0,0.5
Acyl chain remodelling of PC,100,-0.0,0.0,0.0,0,0.5
Acyl chain remodelling of PE,100,-0.0,0.0,0.0,0,0.5
Acyl chain remodelling of PS,800,0.16820536699377153,0.5045642940633647,0.0,0,0.7792356450325741
Acyl chain remodelling of PI,100,-0.0,0.0,0.0,0,0.5
Mitochondrial Fatty Acid Beta_Oxidation,100,-0.0,0.0,0.0,0,0.5
Diseases of metabolism,750,0.18513620930179156,0.5382652032949939,0.0,0,0.7777274260121428
Defects in vitamin and cofactor metabolism,100,-0.0,0.0,0.0,0,0.5
Cobalamin Cbl vitamin B12 transport and metabolism,100,-0.0,0.0,0.0,0,0.5
Metabolism of water_soluble vitamins and cofactors,100,-0.0,0.0,0.0,0,0.5
Metabolism of folate and pterines,100,-0.0,0.0,0.0,0,0.5
Sulfur amino acid metabolism,100,-0.0,0.0,0.0,0,0.5
Metabolism of steroid hormones,100,-0.0,0.0,0.0,0,0.5
Steroid hormones,100,-0.0,0.0,0.0,0,0.5
Amine_derived hormones,100,-0.0,0.0,0.0,0,0.5
Peroxisomal lipid metabolism,100,-0.0,0.0,0.0,0,0.5
Synthesis of very long_chain fatty acyl_CoAs,250,2.0483011393621577,18.035291021092544,0.3103448275862069,200,0.9500399627392627
Fatty Acyl_CoA Biosynthesis,450,1.0657254908449767,12.675256953511505,0.13793103448275862,250,0.8896371372855318
Triglyceride Biosynthesis,450,0.97851430955197,12.867612423600859,0.13793103448275862,300,0.8795800917536821
Transcriptional regulation of white adipocyte differentiation,100,-0.0,0.0,0.0,0,0.5
Mitochondrial biogenesis,100,-0.0,0.0,0.0,0,0.5
Transcriptional activation of mitochondrial biogenesis,100,-0.0,0.0,0.0,0,0.5
Circadian Clock,100,-0.0,0.0,0.0,0,0.5
BMAL1:CLOCKNPAS2 activates circadian gene expression,100,-0.0,0.0,0.0,0,0.5
RORA activates gene expression,100,-0.0,0.0,0.0,0,0.5
YAP1_ and WWTR1 TAZ_stimulated gene expression,100,-0.0,0.0,0.0,0,0.5
Regulation of cholesterol biosynthesis by SREBP SREBF,100,-0.0,0.0,0.0,0,0.5
Activation of gene expression by SREBF SREBP,100,-0.0,0.0,0.0,0,0.5
Cholesterol biosynthesis,100,-0.0,0.0,0.0,0,0.5
Nuclear Receptor transcription pathway,100,-0.0,0.0,0.0,0,0.5
Recycling of bile acids and salts,100,-0.0,0.0,0.0,0,0.5
Bile acid and bile salt metabolism,100,-0.0,0.0,0.0,0,0.5
Synthesis of bile acids and bile salts,100,-0.0,0.0,0.0,0,0.5
Synthesis of bile acids and bile salts via 7alpha_hydroxycholesterol,100,-0.0,0.0,0.0,0,0.5
Synthesis of bile acids and bile salts via 27_hydroxycholesterol,100,-0.0,0.0,0.0,0,0.5
Arachidonic acid metabolism,100,-0.0,0.0,0.0,0,0.5
Synthesis of Leukotrienes LT and Eoxins EX,100,-0.0,0.0,0.0,0,0.5
Fatty acids,100,-0.0,0.0,0.0,0,0.5
Endogenous sterols,100,-0.0,0.0,0.0,0,0.5
Cytochrome P450 _ arranged by substrate type,100,-0.0,0.0,0.0,0,0.5
Phase 1 _ Functionalization of compounds,750,0.08532507904769875,0.1481233822328046,0.0,0,0.7543972066607949
Xenobiotics,100,-0.0,0.0,0.0,0,0.5
Aflatoxin activation and detoxification,200,0.04052415623106478,0.0549867439835167,0.0,0,0.6022365285705751
Glutathione conjugation,200,2.2634516908872224,22.08361894479708,0.3793103448275862,200,0.9569255505526427
Glucuronidation,100,-0.0,0.0,0.0,0,0.5
Cytosolic sulfonation of small molecules,100,-0.0,0.0,0.0,0,0.5
Synthesis and interconversion of nucleotide di_ and triphosphates,100,-0.0,0.0,0.0,0,0.5
Detoxification of Reactive Oxygen Species,900,0.25676311984704614,0.7766653259342472,0.0,0,0.8066121422385931
Metabolism of porphyrins,100,-0.0,0.0,0.0,0,0.5
Purine metabolism,100,-0.0,0.0,0.0,0,0.5
Metabolism of nucleotides,100,-0.0,0.0,0.0,0,0.5
Pyrimidine metabolism,100,-0.0,0.0,0.0,0,0.5
Complex I biogenesis,100,-0.0,0.0,0.0,0,0.5
Respiratory electron transport,100,-0.0,0.0,0.0,0,0.5
Formation of ATP by chemiosmotic coupling,100,-0.0,0.0,0.0,0,0.5
Glyoxylate metabolism and glycine degradation,100,-0.0,0.0,0.0,0,0.5
Pyruvate metabolism,100,-0.0,0.0,0.0,0,0.5
Pyruvate metabolism and Citric Acid TCA cycle,100,-0.0,0.0,0.0,0,0.5
Citric acid cycle TCA cycle,100,-0.0,0.0,0.0,0,0.5
Histidine lysine phenylalanine tyrosine proline and tryptophan catabolism,100,-0.0,0.0,0.0,0,0.5
Mitochondrial tRNA aminoacylation,100,-0.0,0.0,0.0,0,0.5
tRNA Aminoacylation,100,-0.0,0.0,0.0,0,0.5
Cytosolic tRNA aminoacylation,100,-0.0,0.0,0.0,0,0.5
tRNA modification in the nucleus and cytosol,100,-0.0,0.0,0.0,0,0.5
Branched_chain amino acid catabolism,100,-0.0,0.0,0.0,0,0.5
Phase 4 _ resting membrane potential,100,-0.0,0.0,0.0,0,0.5
Mitochondrial translation initiation,100,-0.0,0.0,0.0,0,0.5
Mitochondrial translation termination,100,-0.0,0.0,0.0,0,0.5
Mitochondrial translation,100,-0.0,0.0,0.0,0,0.5
Mitochondrial translation elongation,100,-0.0,0.0,0.0,0,0.5
